Toll-like receptors and IL-7 as potential biomarkers for immune-mediated necrotizing myopathies.
Cytokines
Immune-mediated necrotizing myopathies (IMNMs)
Innate immunity
Macrophages
Toll-like receptors
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
05
06
2023
received:
10
12
2022
accepted:
09
08
2023
medline:
2
11
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
ppublish
Résumé
We aimed to verify whether the immune system may represent a source of potential biomarkers for the stratification of immune-mediated necrotizing myopathies (IMNMs) subtypes. A group of 22 patients diagnosed with IMNM [7 with autoantibodies against signal recognition particle (SRP) and 15 against 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR)] and 12 controls were included. A significant preponderance of M1 macrophages was observed in both SRP
Identifiants
pubmed: 37562045
doi: 10.1002/eji.202250326
doi:
Substances chimiques
Interleukin-7
0
Toll-Like Receptor 4
0
Autoantibodies
0
Biomarkers
0
Signal Recognition Particle
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2250326Informations de copyright
© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Références
Allenbach, Y., Mammen, A. L., Benveniste, O. and Stenzel, W., the Immune-Mediated Necrotizing Myopathies Working Group, 224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul. Disord. 2018. 28: 87-99.
Day, J. A. and Limaye, V., Immune-mediated necrotising myopathy: a critical review of current concepts. Semin. Arthritis Rheum. 2019. 49: 420-429.
Pinal-Fernandez, I., Casal-Dominguez, M., Carrino, J. A., Lahouti, A. H., Basharat, P., Albayda, J., Paik, J. J. et al., Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann. Rheum. Dis. 2016. 76: 681-687.
Watanabe, Y., Uruha, A., Suzuki, S., Nakahara, J., Hamanaka, K., Takayama, K., Suzuki, N. et al., Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J. Neurol. Neurosurg. Psychiatry 2016. 87: 1038-1044.
Allenbach, Y. and Benveniste, O., Peculiar clinicopathological features of immune-mediated necrotizing myopathies. Curr. Opin. Rheumatol. 2018. 30: 655-663.
Kassardjian, C. D., Lennon, V. A., Alfugham, N. B., Mahler, M. and Milone, M., Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol. 2015. 72: 996-1003.
Arouche-Delaperche, L., Allenbach, Y., Amelin, D., Preusse, C., Mouly, V., Mauhin, W., Tchoupou, G. D. et al., Pathogenic role of anti-signal recognition protein and anti-3-hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann. Neurol. 2017. 81: 538-548.
Bergua, C., Chiavelli, H., Allenbach, Y., Arouche-Delaperche, L., Arnoult, C., Bourdenet, G., Jean, L. et al., In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann. Rheum. Dis. 2019. 78: 131-139.
Moran, E. M. and Mastaglia, F. L., Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin. Exp. Immunol. 2014. 178: 405-415.
Preuße, C., Goebel, H. H., Held, J., Wengert, O., Scheibe, F., Irlbacher, K., Koch, A. et al., Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am. J. Pathol. 2012. 181: 2161-2171.
Oda, F., Uzawa, A., Ozawa, Y., Yasuda, M. and Kuwabara, S., Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy. J. Neuroimmunol. 2022. 365: 577833.
Rayavarapu, S., Coley, W., Kinder, T. B. and Nagaraju, K., Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skelet. Muscle 2013. 3: 13.
Cappelletti, C., Baggi, F., Zolezzi, F., Biancolini, D., Beretta, O., Severa, M., Coccia, E. M. et al., Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology 2011. 76: 2079-2088.
Mecoli, C. A., Lahouti, A. H., Brodsky, R. A., Mammen, A. L. and Christopher-Stine, L., High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies. Neurol. Neuroimmunol. Neuroinflamm. 2017. 4: e381.
Li, S., Li, W., Jiang, W., He, L., Peng, Q., Wang, G., Lu, X. et al., The efficacy of tocilizumab in the treatment of patients with refractory immune-mediated necrotizing myopathies: an open-label pilot study. Front. Pharmacol. 2021. 12: 635654.
Ma, X., Gao, H. J., Zhang, Q., Yang, M.-G., Bi, Z.-J., Ji, S.-Q., Li, Y. et al., Endoplasmic reticulum stress is involved in muscular pathogenesis in idiopathic inflammatory myopathies. Front. Cell Dev. Biol. 2022. 10: 791986.
Kawasaki, T. and Kawai, T., Toll-like receptor signaling pathways. Front. Immunol. 2014. 5: 1-8.
Duan, T., Du, Y., Xing, C., Wang, H. Y. and Wang, R. F., Toll-like receptor signaling and its role in cell-mediated immunity. Front. Immunol. 2022. 13: 812774.
Schaefer, L., Complexity of danger: the diverse nature of damage-associated molecular patterns. J. Biol. Chem. 2014. 289: 35237-35245.
Anders, H. J. and Schaefer, L., Beyond tissue injury-damage-associated molecular patterns, Toll-Like Receptors, and inflammasomes also drive regeneration and fibrosis. J. Am. Soc. Nephrol. 2014. 25: 1387-1400.
Piccinini, A. M. and Midwood, K. S., DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010. 2010: 672395.
Brunn, A., Zornbach, K., Hans, V. H., Haupt, W. F. and Deckert, M., Toll-like receptors promote inflammation in idiopathic inflammatory myopathies. J. Neuropathol. Exp. Neurol. 2012. 71: 855-867.
Cappelletti, C., Galbardi, B., Kapetis, D., Vattemi, G., Guglielmi, V., Tonin, P., Salerno, F. et al., Autophagy, inflammation and innate immunity in inflammatory myopathies. PLoS One 2014. 9: e111490.
Tournadre, A., Lenief, V. and Miossec, P. Expression of toll-like receptor 3 and toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum. 2010. 62: 2144-2151.
Marguerat, S., Schmidt, A., Codlin, S., Chen, W., Aebersold, R. and Bähler, J., Quantitative analysis of fission yeast transcriptomes and proteomes in proliferating and quiescent cells. Cell 2012. 151: 671-683.
Shen, L. X., Basilion, J. P. and Stanton, V. P. Jr., Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc. Natl. Acad. Sci. USA 1999. 96: 7871-7876.
Valentini, S., Marchioretti, C., Bisio, A., Rossi, A., Zaccara, S., Romanel, A. and Inga, A., TranSNPs: a class of functional SNPs affecting mRNA translation potential revealed by fraction-based allelic imbalance. iScience 2021. 24: 103531.
Hassan, A. E., Shoeib, S. and Abdelmohsen, E., Toll-like receptor 9 (TLR9) gene C/T (rs352140) polymorphisms in adult primary immune thrombocytopenia. Clin. Appl. Thromb. Hemost. 2020. 26: 1-7.
Bashir, M. A., Afzal, N., Hamid, H., Kashif, M., Niaz, A. and Jahan, S., Analysis of single nucleotide polymorphisms encompassing toll-like receptor (TLR)-7 (rs179008) and (TLR)-9 (rs352140) in systemic lupus erythematosus patients. Adv. Life Sci. 2021. 8: 103-107.
Song, G. G., Choi, S. J., Ji, J. D. and Lee, Y. H., Toll-like receptor polymorphisms and vasculitis susceptibility: meta-analysis and systematic review. Mol. Biol. Rep. 2013. 40: 1315-1323.
Mosaad, Y. M., Metwally, S. S., Farag, R. E., Lotfy, Z. F. and AbdelTwab, H. E., Association between Toll-like receptor 3 (TLR3) rs3775290, TLR7 rs179008, TLR9 rs352140 and chronic HCV. Immunol. Invest. 2019. 48: 321-332.
Lia, A., Annese, T., Fornaro, M., Giannini, M., D'Abbicco, D., Errede, M., Lorusso, L. et al., Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy. Rheumatology (Oxford) 2022. 61: 3448-3460.
Szodoray, P., Alex, P., Knowlton, N., Centola, M., Dozmorov, I., Csipo, I., Nagy, A. T. et al., Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford) 2010. 49: 1867-1877.
Nosalski, R. and Guzik, T. J., IL-15 and IL-7: keys to dysregulated inflammation in acute coronary syndromes. Cardiovasc. Res. 2021. 117: 1806-1808.
van Roon, J. A. G., Glaudemans, K., Bijlsma, J. W. J. and Lafeber, F., Interleukin 7 stimulates tumour necrosis factor α and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann. Rheum. Dis. 2003. 62: 113-119.
Kalinova, D., Kopchev, A., Kolarov, Z. and Rashkov, R., Immune-mediated necrotizing myopathy with anti-SRP autoantibodies and typical clinical presentation. Clin. Med. Rev. Case Rep. 2020. 7: 314.